Find Clinical Trials

Inclusion Criteria: * Participant is currently ≥18-35 years old * Participant is receiving cancer-directed care at Penn State Cancer Institute or Penn State Children's Hospital * Participant has completed all cancer-directed therapy and is at least 1 year from end of cancer treatment (based on date of last cancer-directed treatment) * Participant has access to a computer with internet capability * Participant is fluent in written and spoken English Exclusion Criteria: * Participant is not fluent in written and spoken English * Participant with cognitive inability to participant in the study as determined by the study team * Participants with history of relapsed cancer

Inclusion Criteria: * Women from Granada and nearby areas aged 35 to 60 years * Presence of mild psychological distress or dysthymia symptoms * Physically inactive (not regularly engaging in physical-sport activities \<150 min/week of MVPA) * No previous participation in physical conditioning or sports programs, or no participation within the past six months * No disabling or high-risk health condition that contraindicates participation in a supervised exercise program * Provide informed consent to participate * Availability to attend the training program sessions at one of the scheduled times Exclusion Criteria: * Serious acute or terminal illness * Severe psychiatric illness * Diagnosed chronic cardiac, pulmonary, or metabolic disease * Disabling osteo-muscular pathology (e.g., fracture, sprain) or neuromuscular disorder preventing physical activity * Pregnancy * Taking prescribed medication for dysthymia or sleep disorders, unless on treatment for more than one year with no symptom improvement * Disagreement with the study conditions (e.g., group randomization, attendance at evaluations, etc.) * Not signing the informed consent and/or the participation commitment form

Inclusion Criteria: * -Inclusion Criteria: * Inclusion criteria for PD patients. For the IRCCS INM Neuromed, patients will be recruited from those affiliated with the Center for the Study and Treatment of Parkinson's Disease of the Neuromed Institute of Pozzilli. Presence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, asymmetric onset), one of which must be tremor or bradykinesia: Absence of atypical symptoms such as: i) early postural instability, freezing episodes, cognitive decline, hallucinations, pathological involuntary movements, vertical gaze palsy; ii) confirmed causes of secondary parkinsonism (focal lesions, medications, toxic substances); Documented response to L-dopa or dopamine agonists (or lack of an adequate therapeutic trial with L-dopa or dopamine agonists). -Inclusion criteria forAD patients. For the University of Campania, patients will be selected at the Department of Advanced Medical and Surgical Sciences of the University of Campania "L. Vanvitelli," located at Piazza Miraglia 2, Naples. The Department will establish a collaboration with the Alzheimer's day centers of ASL NA1 (Geriatric Facility "Villa Walpole" - Via Ponti Rossi, 118 - Naples, and Geriatric Facility "Frullone" - Via Comunale del Principe, 16/A - Naples) to identify potential subjects for screening to verify the parameters required for recruitment. The Geriatrics and Internal Medicine Unit (UOC), AOU University of Campania, will also be involved. Patients with AD will be included following a diagnosis of probable Alzheimer's disease according to the McKhann criteria (2011), supported by positive biomarkers for amyloidopathy (amyloid PET or cerebrospinal fluid amyloid assay). Exclusion Criteria: * Pre-existing psychiatric disorders; * Neurodegenerative neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, neuromuscular disorders, epilepsy; * Diagnosis of dementia.

Inclusion Criteria: * Diagnosed type 1 or 2 diabetes and at least one comorbidity (eg, obesity, HIV, heart failure, polycystic ovary syndrome, obstructive sleep apnea, and prediabetes with and without hypertension) * Being able to fill in the Redcap surveys, and install and use the audio diary app. Exclusion Criteria: •Those who cannot use (e.g., no mobile phone, incompatible system), read, type, speak, or understand English in Redcap or the audio diary mobile app.

Inclusion Criteria: * Aged 12-80 years; * Diagnosis confirmed by two psychiatrists per DSM-5; * Stable medication regimen pre-enrollment; * Indicated for neuromodulation OR with visual field defects. Exclusion Criteria: * Major systemic diseases; * Prior neuromodulation within 3 months; * Pregnancy or potential pregnancy; * Metal implants or claustrophobia.

Inclusion Criteria: 1. Age ≥ 18 years, male or female. 2. Histologically or cytologically confirmed HER2-positive advanced breast cancer (IHC 3+, or IHC 2+ with ISH amplification), with known HR status. 3. Have unresectable locally advanced or metastatic disease. If recurrent (after \[neo\]adjuvant therapy), must be at least 6 month treatment free from any trastuzumab and pertuzumab received in the early breast cancer setting for advanced HER2+ disease. 4. Have received 4-8 cycles of pre-study induction therapy including only trastuzumab, pertuzumab, and taxane as first-line of therapy for the treatment of advanced breast cancer prior to study enrollment. Participants are eligible provided they are without evidence of disease progression following completion of induction therapy. 5. CNS Inclusion - Based on screening contrast-enhanced brain magnetic resonance imaging (MRI), participants may have any of the following: No evidence of brain metastases. Untreated brain metastases which are asymptomatic not needing immediate local treatment and, if identified on prior brain imaging, without evidence of progression since starting first-line induction therapy with trastuzumab, pertuzumab, and taxane 6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 7. Have planned to receive maintenance anti-tumor therapy with pyrotinib in combination with HP 8. Negative serum pregnancy test; women of childbearing potential must use a highly effective contraceptive method from study initiation until at least 6 months after the last dose of study medication. 9. Voluntary participation with written informed consent obtained prior to any study-related procedures. Exclusion Criteria: 1. Other malignancy diagnosed within 5 years prior to enrollment. 2. Prior treatment with any tyrosine kinase inhibitor targeting HER2 and/or epidermal growth factor receptor (EGFR) including pyrotinib, lapatinib, tucatinib, neratinib, and afatinib. 3. Patients who are difficult or unable to be followed-up. 4. Other reasons that, in the investigator's judgment, make the patient unsuitable for participation in this study.

Inclusion Criteria: * Resident of LTC for ≥2 weeks * Receiving regular wound care for pressure ulcers * Able to tolerate iVR headset use * (If cognitively apt) able to understand English or French Exclusion Criteria: * Blindness, severe cataracts, or glaucoma * Allergies to synthetic plastics or headset materials * Head or ear wounds preventing headset placement * Peripheral neuropathy * Dangerous or aggressive behaviors in the past 30 days

Inclusion Criteria: * indicating to seek outpatient psychotherapy * elevated levels of self-reported depressive symptoms (Beck Depression Inventory-II (BDI) score \> 13 (out of 63); Kühner et al., 2007) * owning a smartphone * signing the informed consent form Exclusion Criteria: * first session for outpatient psychotherapy is scheduled within four weeks * suicidal ideation (values \> 2 in BDI item 9) * presence of manic symptoms (Mood Disorder Questionnaire (MDQ) score \> 7), - shift work * age below 18 or above 70

Inclusion Criteria: * Age: 18 years and older Gestational status: Term pregnancy Exclusion Criteria: * those with psychological problems

Inclusion Criteria: * Patients with severe preeclampsia undergoing cesarean section * Gestational age \> 32 weeks Exclusion Criteria: * • Age \< 20 years. * Diabetic * Patients with neuromuscular diseases. * Patient refusal. * Contraindications to magnesium sulphate administration * Inability to obtain adequate ultrasound views

Inclusion Criteria: * Those with solid breast masses * Female patients * Those with pathology results Exclusion Criteria: * Hypovascular masses * Cystic breast masses * Cases with mastitis

Inclusion Criteria: * Age ≥18 years * Meeting the diagnostic criteria for ACS * 14 days to 12 months after successful PCI, with stable vital signs * Meeting the diagnostic criteria for depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * HAMD-17 score ≥7 and \<24 (mild-to-moderate depression), with HAMA score \<HAMD score; * Refusal of psychiatric consultation, antidepressant medication, or psychological therapy by the patient or their legal representative after full informed consent * Voluntary participation in the study and signing of the informed consent form Exclusion Criteria: * Severe heart failure (New York Heart Association \[NYHA\] class ≥III) * Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and diastolic blood pressure ≥110 mmHg) * Electrocardiographic abnormalities (first-degree atrioventricular block with PR interval ≥0.20 s, second-degree type II or third-degree atrioventricular block at any time, 24-hour average heart rate ≤50 beats per minute, RR interval ≥3 s) or a history of syncope unrelated to the current ACS * Dialysis-dependent patients * Previous renal sympathetic denervation or vagal ganglion ablation * Expected survival time \<4 months * Pre-PCI diagnosis of severe mental illnesses, including schizophrenia, severe intellectual disability, or substance abuse * Current use of antipsychotic medications * High suicide risk * Pregnant or lactating women * Left ear diseases, acute exacerbation of asthma or chronic obstructive pulmonary disease, or other conditions precluding taVNS treatment * Implanted cardiac pacemaker, implantable cardioverter-defibrillator (ICD), or other implantable stimulators (e.g., vagus nerve stimulator, deep brain stimulator)

Inclusion Criteria: 1. postmenopausal or premenopausal/perimenopausal women ≥ 18 years of age who meet one of the following: a) prior bilateral oophorectomy, or ≥ 60 years of age; or b) age \< 60 years, spontaneous postmenopausal status (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months without other pathological or physiological causes), E2 and FSH at postmenopausal levels; or c) premenopausal or perimenopausal women must be willing to receive LHRH agonists between studies. 2. Female breast cancer patients diagnosed as HR positive and HER2 negative by pathological examination are not suitable for surgical resection or radiation therapy with the purpose of cure. A) ER-positive and/or PR-positive are defined as having positively stained tumor cells representing ≥ 1% of all tumor cells (reviewed and confirmed by the investigator at the site); b) HER2-negative are defined as having 0/1 + by standard immunohistochemistry (IHC); HER2/CEP17 ratio of less than 2.0 by ISH or HER2 gene copy number of less than 4 (reviewed and confirmed by the investigator at the site). 3. ECOG score 0-2. 4. Patients with new stage IV or recurrent metastases with visceral metastases are allowed to enroll patients with visceral crisis (visceral crisis definition includes but is not limited to meeting one of the following: pleural effusion; ascites; abdominal pain caused by liver or peritoneal metastases; rapid worsening of dyspnea at rest that cannot be relieved by pleural effusion drainage; rapid increase in bilirubin \> 1.5 × ULN in the absence of Gilbert 's syndrome or biliary obstruction). 5. adequate bone marrow function, defined as follows: a) neutrophil count (ANC) ≥ 1,500/mm3 (1.5 x 109 L) (no growth factors used within 14 days); b) platelet count (PLT) ≥ 100,000/mm3 (100 x 109 L) (no corrective treatment used within 7 days); c) hemoglobin (Hb) ≥ 8 g/dL (80 g/L) (no corrective treatment used within 14 days). 6. Female subjects who are not postmenopausal or surgically sterile must have a negative serum pregnancy test within 7 days before the first dose and are willing to abstain from sexual intercourse or use a medically recognized highly effective contraceptive measure after signing informed consent, during the study, and for 1 year after the last dose of study drug. 7. Voluntarily join this study, sign informed consent, have good compliance and are willing to cooperate with follow-up. Exclusion Criteria: 1. patients who have previously been treated with CDK4/6 inhibitors and/or capecitabine. 2. patients who relapse within 2 years of adjuvant endocrine therapy. 3. Patients with bone metastases alone regardless of recurrence, metastasis or new stage IV disease. 4. patients with active brain metastases. 5. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), hepatitis B surface antigen positive and HBV DNA ≥ 2000 IU/ml, hepatitis C (hepatitis C antibody positive, and HCV-RNA above the lower limit of detection of the analytical method) or combined hepatitis B and hepatitis C co-infection. 6. The following conditions occurred 6 months before enrollment: myocardial infarction, severe/unstable angina pectoris, NYHA class 2 or higher cardiac insufficiency, ≥ grade 2 persistent arrhythmia (according to NCI CTCAE version 5.0), atrial fibrillation of any grade, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack) or symptomatic pulmonary embolism, and new thrombosis. 7. Complicated with severe infection within 4 weeks before the first dose (such as intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical diagnosis and treatment specifications), or unexplained fever \> 38.5℃ during screening/before the first dose. 8. inability to swallow, bowel obstruction, or the presence of other factors that affect the administration and absorption of the drug. 9. known hypersensitivity to regimen combination therapy drugs and any of their excipients. 10. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 11. Known history of psychotropic substance abuse or drug abuse. 12. Female patients who are pregnant or lactating. 13. Any other condition that the investigator considers the subject unsuitable for participation in this study.

Inclusion Criteria: 1. Any person ≥ 16 years-old suspected of having or diagnosed with congenital heart disease (CHD), other cardiovascular disease (CVD), pulmonary hypertension, connective tissue disease, or genetic syndrome/diagnosis. 2. Additionally, a cohort (Control group A) of control subjects will be enrolled, again ≥16 years-old, self-reported non-smokers without a known history of diabetes mellitus, myocardial infarction, stroke, heart failure, or chronic kidney disease. These controls will be either: 1. A family member or other person accompanying a patient to a clinical encounter; or, 2. A volunteer recruited via an advertisement; or, 3. Another person who volunteers to enroll in HIBR-ACHD. 3. A cohort (Control group B) of comparison subjects who do not have CHD, but have a diagnosis of heart failure or pulmonary hypertension. Exclusion Criteria: * Unable to provide informed consent/assent personally or via a legal guardian. * Considered unsafe to collect the biospecimen determined by either a clinical provider or an HIBR-ACHD investigator. * Overnight hospitalization for non-obstetric reason with discharge in the prior 30 days.

Inclusion Criteria: * Clinically node-negative, DCIS or invasive stage T1-T3 breast cancer confirmed by biopsy * Preoperative axillary ultrasound to confirm clinical node-negative status * Indication for breast cancer surgery with SLNB via axillar incision * Written informed consent according to national regulations Exclusion Criteria: * Patients \< 18 years old. * Indication for breast cancer surgery with SLNB via mastectomy incision * Known allergy for ICG, intravenous contrast or iodine * History of axillary lymph node dissection * Pregnancy or breast-feeding * Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol

Inclusion Criteria: * Patients aged less than 18 years diagnosed with portal hypertension either due to hepatic or extrahepatic causes Exclusion Criteria: * Active variceal bleeding at presentation (hemodynamic instability affects platelet/spleen parameters). * Previous history of variceal bleeding or endoscopic intervention (band ligation/sclerotherapy). * Prior surgical portosystemic shunts or Transjugular Intrahepatic Portosystemic Shunt (TIPS). * Current use of vasoactive drugs for primary prophylaxis (e.g., Non-selective beta-blockers). * Systemic infections or hematological disorders causing independent thrombocytopenia or splenomegaly (to avoid confounding the platelet/spleen ratio).

Inclusion Criteria: * Subject is \> 18 years of age * Clinical and radiological diagnosis of metastatic cancer with histological verification. * White blood cell count: \> 2.0 x 10\^9/L * Haemoglobin: \> 80 g/L * Platelets: \> 50.0 x 10\^9/L * Bilirubin =\< 2.0 times Upper Limit of Normal * Serum creatinine: Within Normal Limits * Blood glucose level not more than 5.9 mmol/L * A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination * Subject is capable to undergo the diagnostic investigations to be performed in the study * Informed consent Exclusion Criteria: * Active current autoimmune disease or history of autoimmune disease * Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) * Known HIV positive or chronically active hepatitis B or C * Administration of other investigational medicinal product within 30 days of screening * Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's

Inclusion Criteria: 1. Age ≥ 18 years. 2. Clinically diagnosed with chronic hepatitis B cirrhosis 3. Acceptance of upper gastrointestinal endoscopy screening or evaluation. 4. Abdominal MRI examination with IVIM sequence within 6 months prior to endoscopy. Exclusion Criteria: 1. Co-existing chronic liver diseases. 2. Previous portosystemic shunt treatment or splenectomy. 3. A history of treatment for upper gastrointestinal varices that affects the assessment. 4. Severe hepatic or splenic iron deposition. 5. Decompensated cirrhosis. 6. Co-existing malignancies.

Inclusion Criteria: 1. Male or female aged 18 to 70 years (inclusive) at the time of signing the informed consent form. 2. Diagnosed with type 2 diabetes mellitus. 3. Voluntarily participate in this study and sign the informed consent form. If a subject is unable to read the informed consent form (e.g., an illiterate subject), an impartial witness must be present during the entire informed consent discussion and must also sign the consent form. 4. At screening, the subject must meet either of the following two criteria: 1. Newly diagnosed with type 2 diabetes within 90 days prior to screening, with no prior use of any antidiabetic medication, and a screening HbA1c level between 8.0% and 11.0% (inclusive). 2. Treated with any one oral antidiabetic drug \[metformin (with a stable daily dose ≥1000 mg or the maximum tolerated dose documented in the patient's medical record), an alpha-glucosidase inhibitor, a sulfonylurea, a glinide, a thiazolidinedione, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), a dipeptidyl peptidase-4 inhibitor (DPP-4i), a glucokinase activator, or an oral glucagon-like peptide-1 receptor agonist\] for at least 60 days prior to screening, with a screening HbA1c level between 7.0% and 11.0% (inclusive). The subject should have been on a stable dose of the medication for at least 30 days prior to screening. 5. Body Mass Index (BMI) \>19 kg/m² and ≤40.0 kg/m². Exclusion Criteria 1. Type 1 diabetes mellitus, monogenic diabetes, diabetes due to pancreatic injury, or other forms of secondary diabetes (e.g., diabetes secondary to Cushing's syndrome or acromegaly). 2. Fasting C-peptide \<1.0 ng/mL (0.34 nmol/L) as measured by the local laboratory. 3. Known or suspected hypersensitivity to the investigational product or related compounds. 4. Participation in any other investigational drug trial within 3 months prior to the start of this study. 5. Use of traditional Chinese herbal medicine for glycemic control within 2 months prior to screening (except for cumulative use ≤7 days). 6. History of acute metabolic complications (e.g., ketoacidosis, lactic acidosis, hyperosmolar coma/state) within the past 6 months. 7. History of decompensated heart failure (NYHA Class IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, or cardiac surgery or vascular reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) within the past 6 months. 8. Severe infection, significant trauma, or major surgery within 30 days prior to screening. 9. History of acute or chronic pancreatitis. 10. Patients with malignancy and a life expectancy of less than one year, active tuberculosis, or acute infection. 11. Current or history of recurrent urinary tract infections and/or genital infections. 12. Patients with a history of hypertension whose blood pressure remains uncontrolled despite antihypertensive medication: systolic blood pressure (SBP) \>180 mmHg and/or diastolic blood pressure (DBP) \>110 mmHg. 13. Systolic blood pressure \<90 mmHg at the screening visit, or patients judged by the clinician to be hypovolemic. 14. Moderate to severe renal impairment (eGFR \<45 mL/min/1.73m²), end-stage renal disease, or patients on dialysis. 15. Men or women of childbearing potential unwilling to use effective contraception during the trial, or women who are pregnant or breastfeeding. 16. Alanine aminotransferase (ALT) \>3.0 x ULN and/or aspartate aminotransferase (AST) \>3.0 x ULN and/or total bilirubin \>2.0 x ULN (upper limit of normal). 17. Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in this clinical trial.

Inclusion criteria: * Being between 18 and 60 years of age. * Being included in the study 3 months after undergoing surgery. * Being able to tolerate compression bandages or compression garments. Exclusion criteria: \- Individuals who need to restart active cancer treatment during the study period. - Being within the first 3 months after surgery.